With FDA Clinical Hold Lifted, Idenix Hopes To Combine Its “Nuc” With A Protease Inhibitor For HCV
This article was originally published in Pharmaceutical Approvals Monthly
Idenix’s IDX184 is the only unpartnered nucleoside polymerase inhibitor for hepatitis C in clinical development. With an FDA hold lifted, the company wants to make quick progress testing ‘184 in interferon-free regimens for HCV.
You may also be interested in...
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.